Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Apr 24:5:1528468.
doi: 10.3389/fdsfr.2025.1528468. eCollection 2025.

Corticosteroids in lung cancer

Vesna Ćeriman Krstić  1   2 , Milija Gajić  2 , Leonida Djukanović  3 , Dragana Jovanović  4
Affiliations
Review

Corticosteroids in lung cancer

Vesna Ćeriman Krstić et al. Front Drug Saf Regul. .

Abstract

Despite significant advances in lung cancer treatment, patients with this disease still present with multiple symptoms that are very hard to control. Corticosteroids are widely used in patients with lung cancer, but without clear evidence for their efficacy. Thus, corticosteroids have been used for the treatment of conditions arising due to the tumor itself, adverse effects of the applied specific therapy and symptom palliation. In this review we are going to summarize clinical indications for corticosteroid use in patients with lung cancer: malignant airway obstruction, superior vena cava syndrome, brain metastases, treatment-related adverse events, anorexia and cachexia, fatigue, dyspnea, nausea and vomiting, spinal cord compression, and pain.

Keywords: brain metastases; cachexia; corticosteroids; dyspnea; immunotherapy; lung cancer; nausea and vomiting; pain.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

References

    1. Aapro M., Caprariu Z., Chilingirov P., Chrápavá M., Curca R. O., Gales L., et al. (2022). Assessing the impact of antiemetic guideline compliance on prevention of chemotherapy-induced nausea and vomiting: results of the nausea/emesis registry in oncology (NERO). Eur. J. Cancer 166, 126–133. 10.1016/j.ejca.2022.01.028 - DOI - PubMed
    1. Arbour K. C., Mezquita L., Long N., Rizvi H., Auclin E., Ni A., et al. (2018). Impact of baseline steroids on efficacy of programmed cell death-1 and programmed death-ligand 1 blockade in patients with non-small-cell lung cancer. J. Clin. Oncol. 36 (28), 2872–2878. 10.1200/JCO.2018.79.0006 - DOI - PubMed
    1. Bower J. E. (2014). Cancer-related fatigue--mechanisms, risk factors, and treatments. Nat. Rev. Clin. Oncol. 11 (10), 597–609. 10.1038/nrclinonc.2014.127 - DOI - PMC - PubMed
    1. Bray F., Laversanne M., Sung H., Ferlay J., Siegel R. L., Soerjomataram I., et al. (2024). Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 74 (3), 229–263. 10.3322/caac.21834 - DOI - PubMed
    1. Bruera E., Roca E., Cedaro L., Carraro S., Chacon R. (1985). Action of oral methylprednisolone in terminal cancer patients: a prospective randomized double-blind study. Cancer Treat. Rep. 69 (7-8), 751–754. - PubMed

LinkOut - more resources